Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer
Spago Nanomedical AB (publ) announced today that Paul Hargreaves has been appointed Chief Development Officer (CDO), starting September 13. He will join the management team and have a key role in the clinical development of the company´s project portfolio.The appointment of Paul Hargreaves as CDO marks an important step for Spago Nanomedical as the company continues to make progress with its unique project portfolio, with the Tumorad[®] candidate drug SN201 rapidly advancing towards clinical trials. This is an opportunity to provide potential treatment for advanced cancers of different